» Articles » PMID: 30352425

Missed Clinical Clues in Patients with Pheochromocytoma/paraganglioma Discovered by Imaging

Abstract

Context: Pheochromocytomas and paragangliomas (PPGLs) are rare but potentially harmful tumors that can vary in their clinical presentation. Tumors may be found due to signs and symptoms, as part of a hereditary syndrome or following an imaging procedure.

Objective: To investigate potential differences in clinical presentation between PPGLs discovered by imaging (iPPGLs), symptomatic cases (sPPGLs) and those diagnosed during follow-up because of earlier disease/known hereditary mutations (fPPGL).

Design: Prospective study protocol, which has enrolled patients from 6 European centers with confirmed PPGLs.

Setting And Patients: Data were analyzed from 235 patients (37% iPPGLs, 36% sPPGLs, 27% fPPGLs) and compared for tumor volume, biochemical profile, mutation status, presence of metastases and self-reported symptoms.

Results: iPPGL patients were diagnosed at a significantly higher age than fPPGLs (p<0.001), found to have larger tumors (p=0.003) and higher metanephrine and normetanephrine levels at diagnosis (p=0.021). Significantly lower than in sPPGL, there was a relevant number of self-reported symptoms in iPPGL (2.9 vs. 4.3 symptoms, p<0.001). In 16.2% of iPPGL, mutations in susceptibility genes were detected, although this proportion was lower than in fPPGL (60.9%) and sPPGL (21.5%).

Conclusions: Patients with PPGLs detected by imaging were older, have higher tumor volume and more excessive hormonal secretion in comparison to those found as part of a surveillance program. Presence of typical symptoms indicates that in a relevant proportion of those patients the PPGL diagnosis had been delayed. Précis: Pheochromocytoma/paraganglioma discovered by imaging are often symptomatic and carry a significant proportion of germline mutations in susceptibility genes.

Citing Articles

Preoperative Management of Catecholamine-Producing Pheochromocytomas and Paragangliomas-Results From a DELPHI Process.

Bechmann N, Chiapponi C, Groeben H, Grasshoff C, Zimmermann P, Walz M J Endocr Soc. 2025; 9(4):bvaf024.

PMID: 40065988 PMC: 11890919. DOI: 10.1210/jendso/bvaf024.


Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients.

Raber W, Schendl R, Arikan M, Scheuba A, Mazal P, Stadlmann V Front Endocrinol (Lausanne). 2024; 15:1419028.

PMID: 39234504 PMC: 11371702. DOI: 10.3389/fendo.2024.1419028.


Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.

Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M Cancers (Basel). 2023; 15(18).

PMID: 37760633 PMC: 10526298. DOI: 10.3390/cancers15184666.


Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma.

Eisenhofer G, Peitzsch M, Bechmann N, Huebner A Front Endocrinol (Lausanne). 2022; 13:901760.

PMID: 35957826 PMC: 9360409. DOI: 10.3389/fendo.2022.901760.


Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.

Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I Clin Transl Oncol. 2021; 23(10):1995-2019.

PMID: 33959901 PMC: 8390422. DOI: 10.1007/s12094-021-02622-9.


References
1.
Peitzsch M, Prejbisz A, Kroiss M, Beuschlein F, Arlt W, Januszewicz A . Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem. 2013; 50(Pt 2):147-55. DOI: 10.1258/acb.2012.012112. View

2.
Mannelli M, Lenders J, Pacak K, Parenti G, Eisenhofer G . Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab. 2012; 26(4):507-15. PMC: 3413196. DOI: 10.1016/j.beem.2011.10.008. View

3.
Eisenhofer G, Brown S, Peitzsch M, Pelzel D, Lattke P, Glockner S . Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem. 2013; 51(Pt 1):38-46. DOI: 10.1177/0004563213487894. View

4.
Riester A, Weismann D, Quinkler M, Lichtenauer U, Sommerey S, Halbritter R . Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol. 2015; 173(6):757-64. DOI: 10.1530/EJE-15-0483. View

5.
Cawood T, Hunt P, OShea D, Cole D, Soule S . Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009; 161(4):513-27. DOI: 10.1530/EJE-09-0234. View